FDA Purple Book · Reference family
somapacitan-beco (Sogroya)
somapacitan-beco is an FDA-licensed reference biologic from Novo Nordisk Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2020
Reference approved
Reference product
351(a)BLA 761156
Sogroya somapacitan-beco
Novo Nordisk Inc.
- Approved
- Aug 28, 2020
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for somapacitan-beco, in chronological order.
Reference approval
Approval date of the reference somapacitan-beco product.
5 yr 10 mo ago
Frequently asked questions
Are there biosimilars approved for somapacitan-beco (Sogroya)?
No 351(k) biosimilars or interchangeable biosimilars referencing somapacitan-beco are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.